AstraZeneca Takes a Long Shot on Lung Cancer Drug Study
- After setback, AstraZeneca says Mystic trial can still succeed
- Shift in FDA approach shows how daunting the challenge is
This article is for subscribers only.
AstraZeneca Plc has a track record of bringing drugs back from the dead. But in the case of the latest setback on a key cancer study, the odds are stacked against the company.
The drugmaker is adamant it has a shot at success after its next-generation treatment failed to slow lung cancer growth more than chemotherapy, a blow that could have killed the trial known as Mystic.